Pregnancy outcome and infant follow-up of fetuses with abnormally increased first trimester nuchal translucency

Human Reproduction

Volumn 15, Issue 9, 2000, Pages 2023-2027

  Maymon, Ron ^a,c   Jauniaux, Eric ^b   Cohen, Ofir ^a   Dreazen, Eli ^a   Weinraub, Zwi ^a   Herman, Arie ^a  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Fetal karyotype; Fetal outcome; Neonatal outcome; Nuchal translucency; Ultrasound

Indexed keywords

ANEUPLOIDY; ARTICLE; CHILD; FETUS; FETUS DISEASE; FETUS KARYOTYPING; FETUS OUTCOME; FIRST TRIMESTER PREGNANCY; FOLLOW UP; HEART DISEASE; HEART VENTRICLE SEPTUM DEFECT; HUMAN; INFANT; MAJOR CLINICAL STUDY; MATERNAL AGE; PARENT COUNSELING; PRENATAL SCREENING; PROGNOSIS; SPONTANEOUS ABORTION; TRANSVAGINAL ECHOGRAPHY;

EID: 0033811456     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/15.9.2023     Document Type: Article

References (34)

1. Increased first trimester nuchal translucency: Pregnancy and infant outcomes after routine screening for Down's syndrome in an unselected antenatal population
2. Science commentary: What is fetal nuchal translucency?
3. Outcome of chromosomally normal livebirth with increased fetal nuchal translucency at 10-14 weeks' gestation
4. Alterations of fetal extracellular matrix in nuchal oedema of Down's syndrome
5. Outcome of fetuses with enlarged nuchal translucency and normal karyotype
6. Fatal cystic hygroma
7. The prognosis of fetuses with transient nuchal translucency in first and early second trimester
8. Nuchal translucency audit: A novel image screening method
9. On-to-on versus on-to-out nuchal translucency measurements
10. Transient increase in nuchal translucency thickness and reversed and diastolic ductus venosus flow in fetus with trisomy 18
11. Cardiac gene expression of atrial natriuretic peptide and brain natriuretic peptide in trisomic fetuses
12. Abnormalities of the heart and great arteries in first trimester chromosomally abnormal fetuses
13. Increased nuchal translucency at 10-14 weeks of gestation as a marker for major cardiac defects
14. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: Population breed cohort study
15. Outcome of nonimmune hydrops fetalis diagnosed during the first half of pregnancy
16. Fetal nuchal translucency: A need to understand the physiological basis
17. Cardiac defects in chromosomally normal fetuses with abnormal ductus venosus blood flow at 10-14 weeks
18. Can nuchal cord cause transient increased nuchal translucency thickness?
19. Increased fetal nuchal translucency: Possible involvement of early cardiac failure
20. Nuchal translucency measurement in normal fetuses
21. Pregnancy outcome and nuchal translucency measurements in fetuses with normal karyotype
22. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation
23. First trimester isolated fetal nuchal lucency: Significance and outcome
24. A critical evaluation of sonar crown-rump length measurements
25. First trimester ultrasound screening for chromosomal defects
26. UK multicentre project on assessment of risk of trisomy 21 by maternal age and nuchal translucency thickness at 10-14 weeks of gestation
27. Defects and syndrome in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks gestation
28. Nuchal fluid accumulation in trisomy 21 detected by vaginosonography in first trimester
29. Increased nuchal translucency as a matter for fetal chromosomal defects
30. Outcome and early childhood follow-up of chromosomally normal fetuses with increased nuchal translucency at 10-14 weeks' gestation
31. Lymphatic vessel hypoplastic in fetuses with Turner's syndrome
32. Ultrasonographic 'soft markers' of fetal chromosomal defects. Detecting them may do more harm than good. Editorial